Sanofi fourth-quarter in line with forecasts; collects damages

8 February 2012

French drug major Sanofi (Euronext: SAN) this morning reported 8.8% growth in fourth-quarter 2011 sales to 8.51 billion euros ($11.16 billion), in-line with consensus forecasts of the same amount, driven by Pharmaceuticals business revenues of 7.22 billion euros (+10.5%), Diabetes business of 1.24 billion euros (+12.5%), US biotech subsidiary Genzyme sales of 831 million euros (+0.8%), Consumer Health Care sales of 645 million euros (+15.4%), generics sales of 488 million euros (+21.0%), and Animal Health business to 470 million euros (+10.0%), offset by 8.1% decline in Sanofi Pasteur sales to 818 million euros.

Business operating income for the quarter increased 11.3% to 2.83 billion euros. Net income attributable to non-controlling interests was 57 million euros (+3.6%); net financial expenses were 113 million euros. Business net income was 2.08 billion euros, up 11.7% at constant exchange rates or 13.0% on a reported basis. Business earnings per share were 1.56 euros (vs consensus 1.56 euros), up 9.2% at CER, or up 10.6% on a reported basis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Generics